MAPT and early-onset autosomal dominant Alzheimer disease: The findings from the four studies illustrate the efficacy of Anle138b against Alzheimer’s disease in mice and in vitro, not only by reducing tau aggregation and affecting amyloid-β but also by rescuing disease phenotypes associated with the disease.